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(56%) patients were men. Annual event rates were 1.7%,
(95% CI 0.4–3.0) for major bleeding, 16.6%, (95% CI
13.0–20.2) for minor bleeding. Mean cost of warfarin
treatment per patient per month was £11.0 (95% CI
10.2–11.6) in patients with no bleeding and £11.9 (95%
CI 10.3–12.5) in patients with minor bleeding (p =
0.095), while in patients with major bleeding the cost was
signiﬁcantly higher (£299.0, 95% CI 74.6–538.9, p =
0.0001). Total cost of warfarin treatment per patient per
year was £159.4 and cost to prevent one stroke per year
was £5260.2. CONCLUSIONS: Warfarin treatment was
cost-effective relative to the costs of stroke. This is likely
to be more cost effective in older people because they have
a higher incidence of stroke.
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OBJECTIVES: Rosuvastatin, a new HMG-CoA reductase
inhibitor has been shown to signiﬁcantly reduce LDL cho-
lesterol. The objective to this analysis was to assess the
cost-effectiveness of rosuvastatin compared to all statins
currently available in Greece. METHODS: A cost-
effectiveness model was developed to compare rosuvas-
tatin with atorvastatin, pravastatin, simvastatin and ﬂu-
vastatin over 52-weeks, from the perspective of the Greek
health care system. Effectiveness was deﬁned as the per-
centage of patients reaching European targets and was
derived from a simulation of clinical trials data. Clinical
practice patterns were derived from a survey among lipid
treatment hospital centers. Patients received a 12-week
prescription of the licensed starting dose. If LDL-C
exceeded the target (3.0mmol/L), patients are titrated to
a higher dose of statin every 12 weeks until they achieve
target or the maximum dose is reached. Patients reaching
target (responders), remain at the last prescribed dose,
followed-up every six months. Only direct medical costs
were included. However, Greek patients can freely use
public or private providers, so both public and private
charges were used. Drug cost estimates are based on rosu-
vastatin expected, and on other statins’ current, ex-
factory prices. Budgetary impact estimates were based on
a hypothesized rosuvastatin market share. RESULTS:
More rosuvastatin-treated patients reach target with the
starting dose. Rosuvastatin patients need fewer up-titra-
tion visits and incur lower costs per responder in their
ﬁrst year of treatment compared to atorvastatin, pravas-
tatin, simvastatin and ﬂuvastatin. Rosuvastatin is more
effective and less costly across the available dose ranges.
For a cohort of 10,000 patients, if rosuvastatin where to
have a 25% market share, the model calculates that there
would be 642 additional responders, reducing annual
costs by €728.204,72 and €83.372,08 in private and
public charges respectively. CONCLUSIONS: Rosuvas-
tatin has been demonstrated to be more effective and a
potentially cost-saving therapy for Greek patients.
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OBJECTIVE: To determine the incremental cost-
effectiveness ratio (ICER) of a new antiplatelet agent,
clopidogrel versus no treatment, in secondary prevention
of atherothrombotic events (myocardial infarction,
ischemic stroke, vascular death) in patients for whom
ASA is not a relevant therapeutic strategy in Hungary.
METHODS: A Markov model designed with 7 clinical
states was used to project the ICER as the cost needed to
achieve an extra life year with clopidogrel compared to
no treatment with a time horizon of 2 years. Based on
Fisher’s analysis the model has combined the rates of 
clinical outcomes reported in CAPRIE (clopidogrel arm)
and in the Antiplatelet Trialists’ Collaboration (no treat-
ment arm) with survival data derived from the Framing-
ham database. Costs of atherothrombotic outcomes were
assessed from Hungarian sources. Payer perspective
(Insurer) was used. The ICER was calculated for patients
who could not take ASA (because of intolerance, allergic
or non responders to ASA). A discount rate of 5% was
applied to both costs and beneﬁts. RESULTS: When com-
pared to no treatment 58 events are avoided per 1000
patients treated with clopidogrel which translates into
297 life years gained. The incremental cost is 241,998
HUF (€968). The ICER of clopidogrel versus no treat-
ment is 814 610 HUF (€3256) per life year saved. Sensi-
tivity analyses shows that results are more sensitive to
discount rate and survival data and less sensitive to costs
of atherothrombotic events. CONCLUSION: Clopido-
grel is shown to be extremely cost-effective strategy in
Hungary when ASA is not a relevant alternative.
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